Vascular Endothelial Growth Factor Inhibitors

Vascular Endothelial Growth Factor Inhibitor

Diabetic Retinopathy

Macular Edema

Retinal Vein Occlusion

<section class="Section" data-sectioncode="34089-3"><a name="S11"></a><a name="section-10"></a><p></p><h1>11 DESCRIPTION</h1><p class="First">LUCENTIS<span class="Sup">®</span> (ranibizumab injection) is a recombinant humanized IgG1 kappa isotype monoclonal antibody fragment designed for intraocular use. Ranibizumab binds to and inhibits the biologic activity of human vascular endothelial growth factor A (VEGF-A). Ranibizumab, which lacks an Fc region, has a molecular weight of approximately 48 kilodaltons and is produced by an <span class="Italics">E. coli</span> expression system in a nutrient medium containing the antibiotic tetracycline. Tetracycline is not detectable in the final product.</p><p>LUCENTIS is a sterile, colorless to pale yellow solution in a single-dose prefilled syringe. LUCENTIS is supplied as a preservative-free, sterile solution in a single-dose container designed to deliver 0.05 mL of 10 mg/mL LUCENTIS (0.5 mg dose prefilled syringe) or 6 mg/mL LUCENTIS (0.3 mg dose prefilled syringe) aqueous solution with 10 mM histidine HCl, 10% α,α-trehalose dihydrate, 0.01% polysorbate 20, pH 5.5.</p></section>

LUCENTIS

0.05 ML ranibizumab 6 MG/ML Injection

0.05 ML ranibizumab 6 MG/ML Injection [Lucentis]

0.05 ML ranibizumab 10 MG/ML Prefilled Syringe

0.05 ML ranibizumab 10 MG/ML Prefilled Syringe [Lucentis]

0.05 ML ranibizumab 6 MG/ML Prefilled Syringe

0.05 ML ranibizumab 6 MG/ML Prefilled Syringe [Lucentis]

ranibizumab

0.05 ML ranibizumab 10 MG/ML Injection

Lucentis

0.05 ML ranibizumab 10 MG/ML Injection [Lucentis]

Psoriasis (PsO)

Psoriatic Arthritis (PsA)

Ankylosing Spondylitis (AS)

Nonradiographic Axial Spondyloarthritis

Taltz

Juvenile Idiopathic Arthritis

Hidradenitis Suppurativa (HS)

Cosentyx

Siliq

Tremfya

Crohn's Disease (CD)

Ulcerative Colitis (UC)

Stelara

Skyrizi

Ilumya

Migraine

Cluster Headache

Migraine Prevention

Emgality

Qulipta

Acute Migraine

Ubrelvy

Nurtec ODT

Vyepti

Aimovig

Ajovy

Breast Cancer: HR+ (HER2-)

Verzenio

Ibrance

Kisqali

Atopic Dermatitis (Eczema)

Cibinqo

Eucrisa

Asthma (injectable)

Asthma OCS Dependent

Nasal Polyposis

Eosinophilic Esophagitis (EoE)

Prurigo Nodularis

Dupixent

Opzelura

Adbry

NSCLC ALK+ OR ROS1+ Disease

Lorbrena

Alecensa

Alunbrig

NSCLC cMET Mutation

Xalkori

Rheumatoid Arthritis (RA)

Xeljanz

Uveitis

Graft Versus Host Disease (GVHD)

Orencia

COVID-19 Treatment

Alopecia Areata

Olumiant

Multiple Sclerosis (MS)

Secondary Progressive Multiple Sclerosis

Zeposia

Rinvoq

Entyvio

Report Adverse Event 

Prescribing Information

Submit MSL Request 

Pharmacy List 

How To Order Lucentis 

Billing & Coding Guide: Myopic Choroidal Neovascularization (mCNV)

Billing & Coding Guide: Wet-Age Related Macular Degeneration (wet AMD)

Billing & Coding Guide: Macular Edema Following Retinal Vein Occlusion (RVO

Billing & Coding Guide: Diabetic Retinopathy (

BIlling & Coding Guide: Diabetic Macular Edema (DME) 

Coverage Authorization Request 

Coverage Authorization Appeals 

Letter of Medical Necessity

Prescriber Service Form 

Patient Consent Form 

Patient Consent Form - Spanish 

Genentech Patient Assistance Program Prescriber Form 

My Patient Solutions - HCP Portal 

Enroll in Patient Savings Program 

Caregiver Brochure: Wet AMD

Wet AMD Staying on Track Brochure 

About Lucentis: Wet AMD 

Side Effects

Before & During Injection 

After Lucentis Injection

FAQs

Lucentis Patient Support Program 

DME Patient Brochure 

DR Caregiver Brochure 

DR Patient Brochure 

About Lucentis: DR & DME

About Lucentis: mCNV

RVO Patient Brochure 

About Lucentis: RVO

Instructions For Use: RVO

Instructions For Use: DR & DME

Instructions For Use: Wet AMD

Instructions For Use: mCNV